Organovo to Present at H.C. Wainwright Nash Investor Conference
15 March 2018 - 11:05PM
Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced
that Chief Executive Officer Taylor J. Crouch is scheduled to speak
at the H.C. Wainwright NASH Investor Conference on Monday, March
19th at 2:40 p.m. Eastern Time (ET). The presentation will be
simultaneously audio webcast at http://www.organovo.com. The audio
webcast will be archived for 90 days following the conference.
Organovo develops liver tissue disease modeling
platforms for non-alcoholic steatohepatitis (“NASH”) and fibrosis
using its proprietary 3D bioprinting technology. The Company’s
healthy and diseased liver tissue systems can facilitate
breakthrough translational research from target discovery to
high-value drug profiling.
About Organovo Holdings,
Inc.Organovo is developing and commercializing a platform
technology to produce and study living tissues that emulate key
aspects of human biology and disease for use in drug discovery,
clinical development, and therapeutic applications. The Company
develops tissue systems through internal research programs and in
collaboration with pharmaceutical, academic and other partners.
Organovo's living tissues have the potential to transform the drug
discovery process, enabling treatments to be developed more
effectively and with greater relevance to performance in human
trials and commercialization. The Company’s ExViveTM Liver and
Kidney Tissues are used in disease modeling for NASH and fibrosis,
high-value drug profiling, target and marker discovery/validation,
and other drug testing. The Company is also advancing a preclinical
program to develop its NovoTissues® liver therapeutic tissues for
critical unmet medical needs, including certain life-threatening
pediatric diseases. The Company has received orphan designation for
its potential treatment of alpha-1-antityrpsin deficiency, its lead
indication within the category of inborn errors of metabolism.
Organovo is changing the shape of life science research and
transforming medical care. Learn more at
www.organovo.com.
Forward-Looking Statements Any
statements contained in this press release that do not describe
historical facts constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of
1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks
and uncertainties. Forward-looking statements include, but
are not limited to, statements regarding the potential for one or
more customer’s electing to move toward framework agreements
involving annual budgets, revenue commitments, and/or dedicated
research plans, the expected costs, timing and operational benefits
of the Company’s restructuring plan, the financial impact of the
Company’s restructuring plan on its future operating costs and
financial results, and statements regarding the potential benefits
and therapeutic uses of the Company’s therapeutic liver
tissue. The factors that could cause the Company's actual
future results to differ materially from current expectations
include, but are not limited to, risks and uncertainties relating
to the Company's ability to develop, market and sell products and
services based on its technology; the expected benefits and
efficacy of the Company's products, services and technology; the
Company’s ability to successfully complete studies and provide the
technical information required to support market acceptance of its
products, services and technology, on a timely basis or at all; the
Company's business, research, product development, regulatory
approval, marketing and distribution plans and strategies,
including its use of third party distributors; the Company’s
ability to recognize deferred revenue; the final results of the
Company's preclinical studies may be different from the Company's
studies or interim preclinical data results and may not support
further clinical development of its therapeutic tissues; the
Company may not successfully complete the required preclinical and
clinical trials required to obtain regulatory approval for its
therapeutic tissues on a timely basis or at all; and the Company’s
ability to meet its fiscal year 2018 outlook. These and other
factors are identified and described in more detail in the
Company's filings with the SEC, including its Annual Report on Form
10-K filed with the SEC on June 7, 2017. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that the Company may issue in the future. Except as required by
applicable law, including the securities laws of the United States,
the Company does not intend to update any of the forward-looking
statements to conform these statements to reflect actual results,
later events or circumstances or to reflect the occurrence of
unanticipated events.
Investor Contact:
Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com
Press Contact:
Jessica Yingling
Little Dog Communications
+1 (858) 480-2411
jessica@litldog.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Nov 2023 to Nov 2024